Celltrion of South Korean will form a JV with Nan Fung Group, a Hong Kong investment firm, to develop and commercialize three Celltrion biosimilars in China. The JV, named Vcell Healthcare, will develop Celltrion biosimilars for major biologic products: Remicade, Rituxan and Herceptin. Each of the three biosimilars have been accepted for use in the US and EU, and Celltrion has already started China trials on the Remicade and Herceptin biosimilars. Vcell also plans to build a biologics facility to manufacture the products in China. Celltrion develops biosimilars and novel biologic drugs.
Source: China Biotoday
